Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesChronic Kidney Disease
You have accessRestricted Access

Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD

Jeffrey M. Saland, Juan C. Kupferman, Christopher B. Pierce, Joseph T. Flynn, Mark M. Mitsnefes, Bradley A. Warady and Susan L. Furth
CJASN December 2019, 14 (12) 1711-1718; DOI: https://doi.org/10.2215/CJN.03110319
Jeffrey M. Saland
1Division of Pediatric Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan C. Kupferman
2Division of Pediatric Nephrology, Maimonides Medical Center, Brooklyn, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher B. Pierce
3Division of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph T. Flynn
4Department of Pediatrics, University of Washington, Seattle, Washington;
5Division of Nephrology, Seattle Children’s Hospital, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark M. Mitsnefes
6Division of Pediatric Nephrology, Cincinnati Children’s Hospital, Cincinnati, Ohio;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley A. Warady
7Division of Pediatric Nephrology, Children’s Mercy Kansas City, Kansas City, Missouri;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan L. Furth
8Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and
9Division of Nephrology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Background and objectives Dyslipidemia, a risk factor for cardiovascular disease, is common in CKD but its change over time and how that change is influenced by concurrent progression of CKD have not been previously described.

Design, setting, participants, & measurements In the CKD in Children study we prospectively followed children with progressive CKD and utilized multivariable, linear mixed-effects models to quantify the longitudinal relationship between within-subject changes in lipid measures (HDL cholesterol, non-HDL cholesterol, triglycerides) and within-subject changes in GFR, proteinuria, and body mass index (BMI).

Results A total of 508 children (76% nonglomerular CKD, 24% glomerular CKD) had 2–6 lipid measurements each, with a median follow-up time of 4 (interquartile range [IQR], 2.1–6.0) years. Among children with nonglomerular CKD, dyslipidemia was common at baseline (35%) and increased significantly as children aged; 43% of children with glomerular CKD had dyslipidemia at baseline and demonstrated persistent levels as they aged. Longitudinal increases in proteinuria were independently associated with significant concomitant increases in non-HDL cholesterol (nonglomerular: 4.9 [IQR, 3.4–6.4] mg/dl; glomerular: 8.5 [IQR, 6.0–11.1] mg/dl) and triglycerides (nonglomerular: 3% [IQR, 0.8%–6%]; glomerular: 5% [IQR, 0.6%–9%]). Decreases in GFR over follow-up were significantly associated with concomitant decreases of HDL cholesterol in children with nonglomerular CKD (−1.2 mg/dl; IQR, −2.1 to −0.4 mg/dl) and increases of non-HDL cholesterol in children with glomerular CKD (3.9 mg/dl; IQR, 1.4–6.5 mg/dl). The effects of increased BMI also affected multiple lipid changes over time. Collectively, glomerular CKD displayed stronger, deleterious associations between within-subject change in non-HDL cholesterol (9 mg/dl versus 1.2 mg/dl; P<0.001) and triglycerides (14% versus 3%; P=0.004), and within-subject change in BMI; similar but quantitatively smaller differences between the two types of CKD were noted for associations of within-subject change in lipids to within-subject change in GFR and proteinuria.

Conclusions Dyslipidemia is a common and persistent complication in children with CKD and it worsens in proportion to declining GFR, worsening proteinuria, and increasing BMI.

  • dyslipidemia
  • pediatric nephrology
  • lipids
  • cardiovascular disease
  • chronic kidney disease
  • child
  • humans
  • HDL cholesterol
  • triglycerides
  • glomerular filtration rate
  • risk factors
  • body mass
  • follow-up studies
  • cholesterol
  • proteinuria
  • dyslipidemias
  • HDL lipoproteins
  • cardiovascular diseases
  • chronic renal insufficiency

Introduction

Dyslipidemia is a well recognized atherosclerotic cardiovascular disease risk factor found commonly in children and adults with CKD. Our baseline cross-sectional study of the CKD in Children (CKiD) study cohort demonstrated a 45% prevalence of dyslipidemia, consistent with more familiar data from adult patients with CKD (1,2). The increased burden of adverse clinical events related to atherosclerotic risk is clear in adults with CKD, whereas the risk to children with CKD is most evident in a younger onset of atherosclerosis-related outcomes among young-adult survivors of childhood-onset CKD and ESKD (3–5). The latest dyslipidemia management guidelines for patients with CKD suggest clinical benefit in initiating lipid-lowering therapy in selected older or higher-risk adults with nondialysis CKD; there is no recommendation to treat younger adults with lower risk, or children (3–5). In particular, the recommendation not to treat dyslipidemia in children with CKD stems from a lack of sufficient data showing safety and benefit, and is consistent with recommendations for younger adults with a lower risk of cardiovascular events within 10 years. Moreover, these guidelines recommend long-term longitudinal research about lipids in children and young-adult survivors of childhood CKD to clarify the risks, outcomes, and unique characteristics of this group. Such information is important for developing a comprehensive understanding of cardiovascular risk in children with CKD, as well as designing studies of potential interventions to improve dyslipidemia in CKD.

Because cross-sectional data demonstrate a positive association between the degree of dyslipidemia and CKD severity manifesting as lower GFR and/or greater proteinuria (1,2,6), it seems logical that the progression of CKD would associate with worsening dyslipidemia longitudinally. However, there are no studies that have prospectively followed individuals, child or adult, with CKD over many years to verify if progression of CKD is associated with progression of dyslipidemia, the magnitude of the link, and which specific elements of CKD associate with specific lipid measures. We contrast this question to the frequently addressed theme of whether baseline dyslipidemia is linked to kidney outcomes such as incident or progressive CKD (7).

To address the gaps in longitudinal knowledge about lipids in children with CKD, our objective was to describe trajectories of lipid measures in children enrolled in the prospective, observational CKiD study. We hypothesized that individual declines in GFR and increases in proteinuria over time would associate with worsening dyslipidemia longitudinally.

Materials and Methods

CKiD is a multicenter, prospective, longitudinal cohort study in the United States and Canada, enrolling children aged 1–16 years with mild to moderate CKD. Its methodology has been previously described and the study protocol has been reviewed by each center’s institutional review board, with participants and parents providing written informed consent/assent according to local requirements (8). Briefly, children were recruited between 2004 and 2019 from 55 clinical sites; in-person follow-up visits occur annually.

The primary outcomes of interest were within-subject changes in fasting lipid levels—specifically, total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglycerides—over follow-up. As part of the study protocol, total cholesterol, HDL cholesterol, and triglycerides are measured every other year, beginning with the first follow-up visit. Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol. This marker is considered of similar epidemiologic value to LDL cholesterol, does not require additional laboratory testing, captures other atherogenic lipoprotein classes such as “remnants,” which can be disproportionately elevated in CKD, and is more robust to nonfasting status as well (9–12). Additionally, dyslipidemia was defined at each patient-visit as having one or more of the following abnormal indicators: hypertriglyceridemia (triglycerides >130 mg/dl), decreased HDL cholesterol (<40 mg/dl), and elevated non-HDL cholesterol (>160 mg/dl). We chose these cut-off points on the following basis: (1) normative The National Health and Nutrition Examination Survey (NHANES) data available for children aged ≥12 years, (2) normative data of the Lipid Research Clinic data set, and (3) levels frequently considered atherogenic in adults (13–15). These cut-off levels are compatible with, or more conservative than (less likely to be classified as dyslipidemic), those suggested by more recent expert guidelines on pediatric dyslipidemia (16,17). Analysis was restricted to data from participants with at least two sets of lipid measurements. Baseline was defined as the first study visit at which lipids were measured (first follow-up visit). The timing of the repeated measures among the participants is shown in Supplemental Table 1.

The primary risk factors of interest were change over follow-up from baseline in GFR, proteinuria, and standardized body mass index (BMIz), respectively. These variables were defined at each visit as xij − xi0, where xij was the GFR, log-transformed proteinuria, or BMIz at the jth visit for the ith person, and xi0 was the corresponding baseline measurement for the ith person. At each visit, GFR was estimated using the CKiD-derived and published “bedside” estimating equation, (18) GFR=41.3×height/sCr, with height measured in meters and sCr indicating serum creatinine, measured in milligrams per deciliter using enzymatic methodology. Proteinuria was quantified by the first-morning urine protein-to-creatinine ratio in mg/mg (UPCR), as previously described (19). Age- and sex-specific body mass index (BMI) percentiles and standardized scores (BMIz) were calculated using 2000 Centers for Disease Control and Prevention standard growth charts for children in the United States. Overweight was defined as a BMI between the 85th and 95th percentiles, and obesity as a BMI over the 95th percentile (20).

Multivariable, linear mixed-effects models were used to quantify the longitudinal relationship between the respective lipid measures and GFR, UPCR, and BMI z-score. The models included the primary risk factors of interest and were adjusted for the following baseline variables: age, sex, black race, glomerular versus nonglomerular CKD diagnosis, GFR, log-transformed UPCR, and BMI z-score. Interaction terms of glomerular diagnosis and the three longitudinal change variables of interest allowed for separate estimates of these parameters for children with glomerular and nonglomerular CKD. The models also included a fixed-effect parameter for time from baseline (i.e., slope) as well as random-effects for both the intercept and slope. As such, the models captured both the between-individual differences in lipids as well as the within-individual lipid changes over follow-up as a function of GFR, UPCR, and BMI z-score. All parameters listed in the table were included simultaneously in the model. Thus, the primary relationships of interest, within-person changes in lipid measures, and their association with concomitant changes in GFR, UPCR, and BMI are adjusted for both baseline effects and follow-up time. As such, these parameters are estimated comparing children of similar attained age over follow-up. Triglycerides were modeled as log-transformed values to meet the assumptions of normality (21). As such, estimated differences and changes in triglycerides are reported as percentages. Additional methodologic details are provided in Supplemental Appendix 1.

Results

At the time of analysis, 891 children with a median GFR of 53 (interquartile range, 39–68) ml/min per 1.73 m2 had enrolled in the CKiD study, of whom 508 had baseline (study year 2, when lipids were first measured) plus at least one set of follow-up lipid measures. Collectively, these children had 1514 person-visits and 2199 years of follow-up. The median follow-up time was 4.0 (interquartile range, 2.1–6.0) years, with more than half (58%) of the children contributing three or more sets of lipid measures. Baseline study visit characteristics are shown in Table 1 for children with nonglomerular and glomerular CKD. On average, children with glomerular CKD were older, more frequently of black race, had shorter duration of CKD, higher GFR, greater proteinuria, higher BMI percentiles, and shorter follow-up in both years and total number of longitudinal lipid measures. Total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride levels, as well as the prevalence of dyslipidemia, were similar between the two diagnosis groups. A total of 16 children (3%) had non-HDL cholesterol >190 mg/dl at baseline. Use of lipid-lowering medication was infrequent (overall, 2%; n=9), although slightly higher in the glomerular CKD group.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics by CKD diagnosis, n=508

Among the nonglomerular group, the cross-sectional prevalence of uncontrolled dyslipidemia increased with increasing age, from 31% to 49% (Cochran–Armitage trend test, P=0.001). As shown in Figure 1, this trend was accompanied by an increase in the proportion of children with nonglomerular CKD presenting with multiple elevated lipid measures. Similar trends were not evident in the glomerular CKD group. For the majority of children with glomerular CKD (those at least 11 years old), dyslipidemia prevalence appeared to be independent of age, although a small sample of younger children with glomerular CKD (n=34) displayed lower dyslipidemia prevalence. Lipid-lowering therapy use also increased significantly over time (P=0.01, data not shown), but remained very uncommon at just 3% (n=51) of all person-visits from 27 children.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cross-sectional prevalence of dyslipidemia by age. Defined as one or more abnormality of triglycerides >130 mg/dL or HDL-cholesterol <40 mg/dL or non-HDL cholesterol >160 mg/dL.

Table 2 provides the parameter estimates from multivariable, linear mixed-effects models for each of the lipid measures of interest. From the study population, 18 patients and 211 person-visits were excluded because of missing covariate data, leaving 490 patients and 1303 person-visits for this adjusted analysis. The parameter estimates labeled “baseline level: between-person differences” capture the associations between baseline lipid levels and risk factors and are analogous to the results of a cross-sectional analysis. Parameter estimates for the primary risk factors of interest appear under the subheading “within-person change from baseline.” For both the nonglomerular and glomerular groups, longitudinal increases in UPCR and BMIz were independently associated with significant concomitant increases in non-HDL cholesterol and triglycerides. A doubling of the UPCR level over follow-up in children with nonglomerular CKD was associated with an expected increase in non-HDL cholesterol of 4.9 mg/dl (95% confidence interval [95% CI], 3.4 to 6.4) in the same time period; among children with glomerular CKD, the expected increase was greater, at 8.5 mg/dl (95% CI, 6.0 to 11.1; P value for heterogeneity=0.01). Likewise, a 0.5-unit increase in age- and sex-specific BMIz over follow-up was associated with an expected concomitant increase in the triglyceride level of 3% (95% CI, 1% to 5%) among children with nonglomerular CKD and 14% (95% CI, 7% to 21%) among children with glomerular CKD (P value for heterogeneity=0.004). With the exception of longitudinal decreases in GFR and longitudinal increases in BMIz in children with nonglomerular CKD, longitudinal changes in HDL cholesterol were not associated with concomitant changes in GFR, UPCR, or BMIz. Compared with changes in UPCR and BMIz, GFR change displayed weaker associations with changes in lipid levels. Observed patterns of change in total cholesterol closely mirrored those of non-HDL cholesterol. In nine out of the 12 (three risk factors and four lipid measurements) estimated associations of interest, children with glomerular CKD displayed stronger, negative point estimates than their nonglomerular CKD counterparts and five of these differences were statistically significant.

View this table:
  • View inline
  • View popup
Table 2.

Results from multivariable, random-effects models of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglycerides on select demographic and clinical factors of interest

As a sensitivity analysis, we ran the models presented in Table 2, excluding those observations (n=51) at which lipid-lowering therapy was reported. The results were qualitatively and quantitatively similar. Additionally, adjusting for duration of CKD in the children with glomerular CKD for whom length of diagnosis is less than attained age did not affect the results of these models.

Finally, the parameter estimates under the subheading “slope” show rates of change (per 2 years) in lipid levels expected among children with no change in GFR, UPCR, and BMIz over follow-up. The results demonstrate, by comparison, that the most significant detrimental changes in lipids were associated with worsening in GFR, UPCR, and BMIz over follow-up (“within-person change from baseline”) and are not merely owing to passage of time since disease onset. Specifically, children presenting with stable (nonchanging) GFR, UPCR, and BMIz over follow-up had statistically significant expected (as seen in the general population at this median age [22]) decreases in total cholesterol (−2.1 mg/dl per 2 years; 95% CI, −3.9 to −0.2) and non-HDL cholesterol (−3.0 mg/dl per 2 years; 95% CI, −4.7 to −1.4) and significant increases in HDL cholesterol (−3.0 mg/dl per 2 years; 95% CI, 0.3 to 1.6) per 2 years. Triglycerides increased on average 5% (95% CI, 2% to 7%) per 2 years.

Discussion

This study demonstrates the degree to which change in kidney function and proteinuria are associated with concomitant dyslipidemic changes in children with CKD. Overall, worsening CKD is accompanied by worsening dyslipidemia. These associations are evident beyond the relationships attributable to baseline effects, are modified by disease type (glomerular versus nonglomerular CKD), and interact with change in BMI.To our knowledge, this study is the first specific examination of the relationship between within-subject longitudinal change in GFR and proteinuria to within-subject longitudinal change in lipids. Traditional methods for analyzing longitudinal data capture relationships between baseline exposures and longitudinal changes in outcome. Such approaches do not simultaneously account for changes in the exposure markers over follow-up, which is both common and expected in clinical practice. We believe that our analysis, capturing the association between longitudinal changes of both important risk factors (GFR, proteinuria, and BMIz) and lipid marker outcomes of interest, is novel and unique. Moreover, because dyslipidemia is an intermediate marker of cardiovascular risk, the ability to track these changes precisely over an extended period is an important step toward the ultimate goal of understanding how cardiovascular outcomes relate to earlier and variable degrees of exposure. Our results strengthen the concept that slowing CKD progression and preventing obesity should slow the development of dyslipidemia and, subsequently, cardiovascular disease. Moreover, in studying the effect of CKD on development of dyslipidemia in children, there was a comparatively low level of confounding. Unlike adults with CKD, most children have primary causes of CKD and do not commonly present with competing causes of dyslipidemia other than obesity (if present). In that respect, our cohort allows perhaps the best possible model of this pathophysiologic complication of CKD in humans, making our findings generalizable to other populations with CKD. The median age of our cohort was around 12 years, and in healthy children at that age, total cholesterol normally begins to fall over time (22) (which our data supports both at baseline and longitudinally). By way of contrast, this allowed additional opportunity to demonstrate the effects of CKD having an opposing effect.

The strength of the within-subject analysis rests in comparing each patient to themselves over time. Although we were able to demonstrate that the point prevalence of dyslipidemia increased over time in the cohort as a group, this finding is potentially confounded because of the changing construct of the cohort over time and subsequent changes in the cohort characteristics, such as the proportion of participants with glomerular disease, the average BMI percentile, and the median GFR. One reason for this is that patients requiring dialysis or transplant exit the study during follow-up. The within-subject analysis also provides a level of precision exceeding both the baseline analysis and cohort-level analysis, and minimizes confounding by allowing an individual to serve as their own control. Thus, it was possible to demonstrate that decreasing GFR affected HDL and non-HDL cholesterol, whereas worsening proteinuria affected non-HDL cholesterol and triglycerides; meanwhile, worsening BMI affected HDL and non-HDL cholesterol, and triglycerides. The success of this approach suggests that the use of within-subject exposure change analysis may yield additional information in other longitudinal cohorts as well. For example, it is interesting to note that in the Study of Heart and Renal Protection (SHARP) study, LDL cholesterol in the placebo group was overall nearly unchanged over 4 years, despite the fact that CKD was progressing (23). The relationship between within-subject changes in CKD and lipids was not reported in either the placebo or the treatment group. Our results suggest post hoc analyses considering individuals’ changes in GFR, proteinuria, and BMI over time might yield additional information from that study. Although our analysis additionally presents expected changes in the lipid measures of interest over time for children with stable (nonchanging) GFR, UPCR, and BMIz over follow-up, these results are limited in scope epidemiologically because the majority of children in the study have progressing CKD; nonetheless, these results largely match observations in the healthy childhood population at the same median baseline age (22).By demonstrating that CKD progression (defined as a decline in GFR or worsening proteinuria) is associated with worsening dyslipidemia, our study suggests that it remains important to investigate the underlying mechanisms as they are not fully understood. Recent findings support insulin resistance and increased ApoC-III as important factors in CKD-related dyslipidemia (24–26). Basic and translational research findings support additional factors such as reduced levels of lipoprotein lipase in target tissues, as well as abnormal levels of lipoprotein receptors (27). Such lines of investigation could be useful if they suggest CKD-specific mechanisms of disease that may have targeted avenues of treatment.

Although the focus of this study was the relationship between changes in GFR and proteinuria and change in lipids, it is also important to note that longitudinal increases in BMI were independently associated with concomitant dyslipidemic changes. It is notable that although these effects were observed for both glomerular and nonglomerular subgroups, with the exception of HDL cholesterol, the effect of BMI on lipids was much greater in the glomerular disease category (versus nonglomerular). We suspect that certain treatments for glomerular disease, especially steroids, may lead to both the obesity and dyslipidemia that are involved in both processes; this observed interaction merits further study. Regardless, obesity and its antecedents, such as low physical activity and high-calorie diets, must be highlighted as modifiable risk factors for dyslipidemic progression (28,29).

The current observation that worsening GFR and worsening dyslipidemia are associated is generally consistent with our previous cross-sectional finding that dyslipidemia was associated with lower GFR among the patients with nonglomerular CKD in our cohort (30). Nonetheless, dyslipidemia as a risk factor for CKD progression has been inconsistently demonstrated in other studies (31–34). In the Chronic Renal Insufficiency Cohort (CRIC) study of adults with CKD, there was no overall association. In fact, subgroup analysis in patients without significant proteinuria demonstrated that higher LDL cholesterol was associated with a 26% lower risk of the composite kidney end point (7). However, in the CRIC study, about one fifth of the patients had preexisting vascular disease, more than half were already receiving lipid-lowering agents, and more than half had diabetes. This again highlights a strength of our study, which is the opportunity to study the relationship between CKD progression and dyslipidemia in individuals with almost no additional confounding clinical factors. Nonetheless, our study is observational and we cannot infer causality.

Guidelines for lipid management of children with CKD specifically suggest no pharmacologic treatment (such as statins) and have suggested the need for further research to fill specific knowledge gaps (3). As a prospective, observational cohort study, our data does not clarify any threshold for treatment, but does address the gaps in knowledge; here, we demonstrate a persistently high prevalence of dyslipidemia as a cardiovascular risk exposure in children, which increases concomitantly with the progression of CKD. This strengthens the idea that disease duration should be considered in risk assessment and guideline development, and not just age. Further follow-up of the CKiD cohort may prove useful in that regard if future data allow us to link disease duration to eventual cardiovascular outcomes.

Despite the strengths of our study, there are also several weaknesses and analytic challenges. Loss of patients from the cohort because of progression to ESKD may present selection bias in that our analysis does not include as many patient-years of data for that subset of patients that progressed most quickly. However, if this bias exists, we will most likely be underestimating the strength of the association. Change in lipids during childhood, and particularly during puberty, is a known source of variation (35,36). We adjusted for age and sex in the analysis to account for this phenomenon, but residual confounding may remain. Although the relationships we explored and quantified may differ across age groups, we were not able to further stratify our analysis because of data size limitations. Also, although a subset of patients had a baseline measure of insulin resistance, it was not measured thereafter, so we were unable to analyze that relationship longitudinally. Finally, our study does not address surrogate markers of lipid-mediated vascular disease, such as intimal medial thickness or pulse-wave velocity.

In conclusion, dyslipidemia remains common among children with CKD over many years. Individuals with CKD develop, maintain, and experience worsening of dyslipidemia over time in proportion to the degree of baseline CKD and the progression of CKD over time. Declining GFR and worsening proteinuria are independently associated with worsening dyslipidemia. Within-subject change in GFR and proteinuria over time, in addition to baseline status, should be incorporated into future observational and interventional studies in patients with CKD.

Disclosures

Dr. Flynn, Dr. Furth, Dr. Kupferman, Dr. Mitsnefes, Dr. Pierce, Dr. Saland, and Dr. Warady have nothing to disclose.

Funding

The CKD in Children (CKiD) study is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; U01-DK-66143 (to Dr. Warady), U01-DK-66174 (to Dr. Furth), U01-DK-082194, and U01-DK-66116), with additional funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute. Dr. Flynn is supported by a grant from NIDDK (U01-DK066143). Dr. Furth and Dr. Warady are supported by grants from the National Institutes of Healthhttps://doi.org/10.13039/100000002. Dr. Mitsnefes, Dr. Pierce, and Dr. Saland are supported by grants from the NIDDK related to the CKiD study.

Supplemental Material

This article contains the following supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.03110319/-/DCSupplemental.

Supplemental Table 1.

Supplemental Appendix 1.

Acknowledgments

We wish to thank the CKD in Children (CKiD) study participants and their families, as well as the site investigators, for many years of dedication to this project.

Data in this manuscript were collected by the CKiD prospective cohort study with clinical coordinating centers (principal investigators) at Children’s Mercy Hospital and the University of Missouri−Kansas City (Dr. Warady), Children’s Hospital of Philadelphia (Dr. Furth), Central Biochemistry Laboratory (Dr. George Schwartz) at the University of Rochester Medical Center, and data coordinating center (Dr. Alvaro Muñoz) at the Johns Hopkins Bloomberg School of Public Health. The CKiD website can be found at www.statepi.jhsph.edu/ckid.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received March 13, 2019.
  • Accepted October 9, 2019.
  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Saland JM,
    2. Pierce CB,
    3. Mitsnefes MM,
    4. Flynn JT,
    5. Goebel J,
    6. Kupferman JC,
    7. Warady BA,
    8. Furth SL; CKiD Investigators
    : Dyslipidemia in children with chronic kidney disease. Kidney Int 78: 1154–1163, 2010pmid:20736985
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kasiske BL
    : Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S142–S156, 1998pmid:9820472
    OpenUrlPubMed
  3. ↵
    1. Sarnak MJ,
    2. Bloom R,
    3. Muntner P,
    4. Rahman M,
    5. Saland JM,
    6. Wilson PW,
    7. Fried L
    : KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis 65: 354–366, 2015pmid:25465166
    OpenUrlPubMed
    1. Wanner C,
    2. Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members
    : KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int 85: 1303–1309, 2014pmid:24552851
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kidney: Disease Improving Global Outcomes (KDIGO) Lipid Work Group
    : KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 3: 259–305, 2013
    OpenUrlCrossRef
  5. ↵
    1. Tsimihodimos V,
    2. Mitrogianni Z,
    3. Elisaf M
    : Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J 5: 41–48, 2011pmid:21643500
    OpenUrlPubMed
  6. ↵
    1. Rahman M,
    2. Yang W,
    3. Akkina S,
    4. Alper A,
    5. Anderson AH,
    6. Appel LJ,
    7. He J,
    8. Raj DS,
    9. Schelling J,
    10. Strauss L,
    11. Teal V,
    12. Rader DJ; CRIC Study Investigators
    : Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol 9: 1190–1198, 2014pmid:24832097
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Furth SL,
    2. Cole SR,
    3. Moxey-Mims M,
    4. Kaskel F,
    5. Mak R,
    6. Schwartz G,
    7. Wong C,
    8. Muñoz A,
    9. Warady BA
    : Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1: 1006–1015, 2006pmid:17699320
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Virani SS
    : Non-HDL cholesterol as a metric of good quality of care: Opportunities and challenges. Tex Heart Inst J 38: 160–162, 2011pmid:21494527
    OpenUrlPubMed
    1. Srinivasan SR,
    2. Frontini MG,
    3. Xu J,
    4. Berenson GS
    : Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: The Bogalusa Heart study. Pediatrics 118: 201–206, 2006pmid:16818566
    OpenUrlAbstract/FREE Full Text
    1. Saland JM,
    2. Ginsberg HN
    : Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 22: 1095–1112, 2007pmid:17390152
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hegele RA
    : CETP inhibitors - a new inning? N Engl J Med 377: 1284–1285, 2017pmid:28953440
    OpenUrlPubMed
  10. ↵
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    : Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high Blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421, 2002pmid:12485966
    OpenUrlFREE Full Text
    1. Christensen B,
    2. Glueck C,
    3. Kwiterovich P,
    4. Degroot I,
    5. Chase G,
    6. Heiss G,
    7. Mowery R,
    8. Tamir I,
    9. Rifkind B
    : Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: The Prevalence Study of the Lipid Research Clinics Program. Pediatr Res 14: 194–202, 1980pmid:6966785
    OpenUrlPubMed
  11. ↵
    1. Hickman TB,
    2. Briefel RR,
    3. Carroll MD,
    4. Rifkind BM,
    5. Cleeman JI,
    6. Maurer KR,
    7. Johnson CL
    : Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: Data from the Third National Health and Nutrition Examination Survey. Prev Med 27: 879–890, 1998pmid:9922071
    OpenUrlCrossRefPubMed
  12. ↵
    1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
    2. National Heart, Lung, and Blood Institute
    : Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics 128[Suppl 5]: S213–S256, 2011pmid:22084329
    OpenUrlFREE Full Text
  13. ↵
    1. McBride PE,
    2. Kavey RE
    : Lipid screening and treatment recommendations for children and adolescents. Pediatr Ann 41: 1–10, 2012pmid:22765031
    OpenUrlPubMed
  14. ↵
    1. Schwartz GJ,
    2. Muñoz A,
    3. Schneider MF,
    4. Mak RH,
    5. Kaskel F,
    6. Warady BA,
    7. Furth SL
    : New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3): 629–637, 2009
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Schwartz GJ,
    2. Furth S,
    3. Cole SR,
    4. Warady B,
    5. Muñoz A
    : Glomerular filtration rate via plasma iohexol disappearance: Pilot study for chronic kidney disease in children. Kidney Int 69: 2070–2077, 2006pmid:16612328
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kuczmarski RJ,
    2. Ogden CL,
    3. Guo SS,
    4. Grummer-Strawn LM,
    5. Flegal KM,
    6. Mei Z,
    7. Wei R,
    8. Curtin LR,
    9. Roche AF,
    10. Johnson CL
    : 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11 (246): 1–190, 2002pmid:12043359
    OpenUrlPubMed
  17. ↵
    1. Bland JM,
    2. Altman DG
    : Transformations, means, and confidence intervals. BMJ 312: 1079, 1996pmid:8616417
    OpenUrlFREE Full Text
  18. ↵
    1. Cook S,
    2. Auinger P,
    3. Huang TT
    : Growth curves for cardio-metabolic risk factors in children and adolescents. J Pediatr 155: S6 e15–S6 e26, 2009
    OpenUrl
  19. ↵
    1. Baigent C,
    2. Landray MJ,
    3. Reith C,
    4. Emberson J,
    5. Wheeler DC,
    6. Tomson C,
    7. Wanner C,
    8. Krane V,
    9. Cass A,
    10. Craig J,
    11. Neal B,
    12. Jiang L,
    13. Hooi LS,
    14. Levin A,
    15. Agodoa L,
    16. Gaziano M,
    17. Kasiske B,
    18. Walker R,
    19. Massy ZA,
    20. Feldt-Rasmussen B,
    21. Krairittichai U,
    22. Ophascharoensuk V,
    23. Fellström B,
    24. Holdaas H,
    25. Tesar V,
    26. Wiecek A,
    27. Grobbee D,
    28. de Zeeuw D,
    29. Grönhagen-Riska C,
    30. Dasgupta T,
    31. Lewis D,
    32. Herrington W,
    33. Mafham M,
    34. Majoni W,
    35. Wallendszus K,
    36. Grimm R,
    37. Pedersen T,
    38. Tobert J,
    39. Armitage J,
    40. Baxter A,
    41. Bray C,
    42. Chen Y,
    43. Chen Z,
    44. Hill M,
    45. Knott C,
    46. Parish S,
    47. Simpson D,
    48. Sleight P,
    49. Young A,
    50. Collins R; SHARP Investigators
    : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181–2192, 2011pmid:21663949
    OpenUrlCrossRefPubMed
  20. ↵
    1. Chan DT,
    2. Dogra GK,
    3. Irish AB,
    4. Ooi EM,
    5. Barrett PH,
    6. Chan DC,
    7. Watts GF
    : Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III. J Lipid Res 50: 2524–2531, 2009pmid:19542564
    OpenUrlAbstract/FREE Full Text
    1. Ooi EM,
    2. Chan DT,
    3. Watts GF,
    4. Chan DC,
    5. Ng TW,
    6. Dogra GK,
    7. Irish AB,
    8. Barrett PH
    : Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res 52: 794–800, 2011pmid:21297177
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Saland JM,
    2. Satlin LM,
    3. Zalsos-Johnson J,
    4. Cremers S,
    5. Ginsberg HN
    : Impaired postprandial lipemic response in chronic kidney disease. Kidney Int 90: 172–180, 2016pmid:27162092
    OpenUrlPubMed
  22. ↵
    1. Vaziri ND
    : Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262–F272, 2006pmid:16403839
    OpenUrlCrossRefPubMed
  23. ↵
    1. Clark SL,
    2. Denburg MR,
    3. Furth SL
    : Physical activity and screen time in adolescents in the chronic kidney disease in children (CKiD) cohort. Pediatr Nephrol 31: 801–808, 2016pmid:26684326
    OpenUrlPubMed
  24. ↵
    1. Chen W,
    2. Ducharme-Smith K,
    3. Davis L,
    4. Hui WF,
    5. Warady BA,
    6. Furth SL,
    7. Abraham AG,
    8. Betoko A
    : Dietary sources of energy and nutrient intake among children and adolescents with chronic kidney disease. Pediatr Nephrol 32: 1233–1241, 2017pmid:28210840
    OpenUrlPubMed
  25. ↵
    1. Warady BA,
    2. Abraham AG,
    3. Schwartz GJ,
    4. Wong CS,
    5. Muñoz A,
    6. Betoko A,
    7. Mitsnefes M,
    8. Kaskel F,
    9. Greenbaum LA,
    10. Mak RH,
    11. Flynn J,
    12. Moxey-Mims MM,
    13. Furth S
    : Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 65: 878–888, 2015pmid:25799137
    OpenUrlCrossRefPubMed
  26. ↵
    1. Chawla V,
    2. Greene T,
    3. Beck GJ,
    4. Kusek JW,
    5. Collins AJ,
    6. Sarnak MJ,
    7. Menon V
    : Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 5: 1582–1587, 2010pmid:20558558
    OpenUrlAbstract/FREE Full Text
    1. Tsuruya K,
    2. Yoshida H,
    3. Nagata M,
    4. Kitazono T,
    5. Iseki K,
    6. Iseki C,
    7. Fujimoto S,
    8. Konta T,
    9. Moriyama T,
    10. Yamagata K,
    11. Narita I,
    12. Kimura K,
    13. Kondo M,
    14. Asahi K,
    15. Kurahashi I,
    16. Ohashi Y,
    17. Watanabe T
    : Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: A longitudinal study in a large Japanese population. Am J Kidney Dis 66: 972–983, 2015pmid:26145254
    OpenUrlCrossRefPubMed
    1. Lin J,
    2. Khetarpal SA,
    3. Terembula K,
    4. Reilly MP,
    5. Wilson FP
    : Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: A longitudinal study. BMC Nephrol 16: 130, 2015pmid:26238454
    OpenUrlPubMed
  27. ↵
    1. Samuelsson O,
    2. Mulec H,
    3. Knight-Gibson C,
    4. Attman PO,
    5. Kron B,
    6. Larsson R,
    7. Weiss L,
    8. Wedel H,
    9. Alaupovic P
    : Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12: 1908–1915, 1997pmid:9306342
    OpenUrlCrossRefPubMed
  28. ↵
    1. Jolliffe CJ,
    2. Janssen I
    : Distribution of lipoproteins by age and gender in adolescents. Circulation 114: 1056–1062, 2006pmid:16940191
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Dai S,
    2. Yang Q,
    3. Yuan K,
    4. Loustalot F,
    5. Fang J,
    6. Daniels SR,
    7. Hong Y
    : Non-high-density lipoprotein cholesterol: Distribution and prevalence of high serum levels in children and adolescents: United States National Health and Nutrition Examination Surveys, 2005-2010. J Pediatr 164: 247–253, 2014pmid:24139441
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (12)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 12
December 06, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD
Jeffrey M. Saland, Juan C. Kupferman, Christopher B. Pierce, Joseph T. Flynn, Mark M. Mitsnefes, Bradley A. Warady, Susan L. Furth
CJASN Dec 2019, 14 (12) 1711-1718; DOI: 10.2215/CJN.03110319

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD
Jeffrey M. Saland, Juan C. Kupferman, Christopher B. Pierce, Joseph T. Flynn, Mark M. Mitsnefes, Bradley A. Warady, Susan L. Furth
CJASN Dec 2019, 14 (12) 1711-1718; DOI: 10.2215/CJN.03110319
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Funding
    • Supplemental Material
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Chronic Kidney Disease

  • Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
  • Patient-Reported Symptoms and Subsequent Risk of Myocardial Infarction in Chronic Kidney Disease
  • Trajectories of Uremic Symptom Severity and Kidney Function in Patients with Chronic Kidney Disease
Show more Chronic Kidney Disease

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • dyslipidemia
  • pediatric nephrology
  • lipids
  • cardiovascular disease
  • chronic kidney disease
  • child
  • humans
  • HDL cholesterol
  • triglycerides
  • glomerular filtration rate
  • risk factors
  • body mass
  • follow-up studies
  • cholesterol
  • proteinuria
  • dyslipidemias
  • HDL lipoproteins
  • Cardiovascular Diseases
  • chronic renal insufficiency

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire